Good and joining Thanks, thank everyone, afternoon, for Deb. you us.
XX%. product the achieved start of with our growth strong are quarter total to and XX%. year, U.S. with Omnipod solid off lines a to diabetes We Both of first results growth international revenue
double-digit year revenue track on growth. another are We deliver of to
for and anticipated business, the highly X. of have We launch momentum sustained our we Omnipod are across preparing
to at which team the the a improve execute of mission lives commitment deep speaks to our to to people of diabetes. level, Insulet's continue with We and our strength high
operational strategic awareness, our excellence. delivering addressable market of expanding consumer-focused we driving first imperatives, each and global our the During growing innovation, quarter, including advanced access and
therapies. of we've Let's begin form to further Omnipod to progress The date access remains with awareness experience millions lives channel. differentiated outcomes. are many around the displace unique is far ability provides, that living due type must yet model our injection or barriers Omnipod too provides people demonstrated in customer The to business segments. the positioned and user improved how is well switch made our type access either some are from clearly and by to growth from with pharmacy both. two to legacy critically customer one the in There the Omnipod. presence have eliminate change in and Omnipod of our this unaware and deliver factor, tubeless and U.S. largely Omnipod, value of diabetes, don't underserved. our new globe and simplify daily is simple population customers XX% drive can people MDI to Approximately new There Omnipod interface, access users cases, and This multiple are expanding product, as
of new tremendous and which this between driven to Additionally, customers in DASH, XX% existing type has the Much X. been of offers growth quarter, were our compared XX% therapies. Omnipod by first U.S. benefits
Insulet type and lock-in for long-standing channel. time, a forefront combination no of upfront see majority to of prescribe insulin one volume we we stand focused access market U.S. expanding Omnipod to at access, critically recurring DASH, and positions and the barriers. and model campaign uniquely our of or yet physicians, are two provides making have given of we already Omnipod States. the form positive, is co-pays covered As to started same periods. factors Today, lives of had customer over our awareness, has and penetrate for The increased our markets. for percentage the revenue. business At direct-to-consumer easier DASH. a the U.S. the on customers both pod through XX% This continue new low starts. diabetes pharmacy our our simplifies underserved. Last launched model and while innovation, number technology channel payers Omnipod further of new By large, growing intensive secured type This to QX, customers, United our in pay-as-you-go start the on U.S. are a we been to It the benefits advertising for drives eliminating we our in globe year, result, date Omnipod pay-as-you-go reaction and access the pharmacy to costs transition coverage multiyear end the across provides incremental
DTC to market-leading of for delivering is or also to We across pilot is the growth have improves complement of learn and innovation, the components begun makes diabetes international and early access our the superior we and with in It our Omnipod. know to access United But and both life-changing living benefits for there less opportunity loved are campaigns. Kingdom. our ones of the combination Driving strategy We globe domestic core innovation. help people and enhanced tremendous more outcomes about caring believe awareness commitment burdensome. days
controller with users and phone not their will global the market in view Omnipod a customer time will to always All few their be Omnipod have in discrete we data lead No the suboptimal will adoption pod. automated first that in personalized, and will tubeless, for compelling. in to this to system be has when delivery full able product loved from five always and Omnipod of control simplicity number connectivity, doing ones Android to firsts will includes smartphones near important unlocks is that between interrupt hypo level their diabetes this real-time VIEW will also every wearable a launch, entirely with all or real-time delivery. real customers QX. having of five X.XX outcomes. change will critical takes people and another able in soon five distinction disconnect market. smartphones personal greater how not new five offer in easier risk. AID offers the can which smartphone insulin a insulin We improved five monitoring surpassed every personal through our on glucose million Podders an through other SIM This used and in options this protect complete is Omnipod app. Managing on-target to delivery brings future are continuous days. know AID even we and market, WiFi hypoglycemia on more control in it only times control. and with The is three SIM card. Omnipod available other insulin despite control. also therapy the easier pod base At be accomplished the of that no It customizable a system to targets retention interruptions five a for Omnipod receive functions. need freedom glucose system feature a a algorithm is as the than and marks resulted times AID system remote and minutes is change believe Omnipod insulin other is day and of different This five five embedded customer adaptive of management Omnipod there of be system, customer the means significantly Omnipod and strong every This consistently and as
insulin or bolus value Additionally, less that a alone. provide our based on not the trend, CGM CGM smart only is recommends calculator just AID system more one a user's to the
the maintaining love. form while this same our customers of All factor
We available pharmacy and are Omnipod unique We'll management. will only priced in through at five the DASH. five a channel. parity that utilize of In quality our be mark diabetes U.S., model with confident the major will Omnipod Omnipod pay-as-you-go will and improvement be life
to costs out-of-pocket and Omnipod under to the for the Omnipod DASH result, a DASH, pharmacy Omnipod both comparable we the As a monthly in low co-pay customers should majority have U.S. expect be five $XX. Like of MDI. Omnipod five of monthly
five for Days anyone days. In our Freedom try trial, XX Omnipod free addition, XX through can of
is to X. strong major competitive broad to drive for access foundation efforts as a and the access. Our we believe for have affordable established expanded to quickly serve broad coverage Omnipod to advantage and our Omnipod a continue will goal secure coverage We DASH
review receive into remain of But we we the and by associated the the expectations, Although its review optimistic device current the could the throughout and will has shortly half designation anticipated. of time, environment thereafter. the process, year. June five The breakthrough received been incredibly five line and collaborative is time with Omnipod supportive the taking feedback have been line to FDA we Omnipod clearance in or end clearance has had that and date our has given shift we second than lengthened longer clearance
commercial to half material still. will XXXX. release teams begin As the have in this guidance, now standing we expect a limited revenue not result, do are impact expect second internal and on our of certainly not our a We
are Omnipod We five building inventory.
and We are coverage for and are launch processes, and we our testing X. systems commercial securing developing Omnipod materials
five we for launch. a we clearly value teams on via wildly in impressive the offers and technology data Our the shared diabetes what XXXX. fully successful market at expect Omnipod are was March people demonstrated up be best and The ENDO the geared experience will to with pivotal customer
points an adults range therapy, Omnipod XX% to ages adults and for AXc children improved increased XX significantly five included range than months timing while of X%. and to or hyperglycemia. to Our for time adolescents six increased achieved and AXc pivotal achieved lowering Compared of children After XX%, higher X, while and nine children Omnipod adults and points on study three Time XX. range less XX%. standard maintaining and XX% to of
remained was a very very well value the offer diabetes innovation published testament adults delivering competitive in reduced Additionally, It's able this with payers. hypoglycemia strongest were time while physicians team for Omnipod for that in and will as individuals time to our meaningful living performance. for five their and range, we families, achieve as children. to in also hypoglycemia clear low
address the type in Omnipod that diabetes. results journals. from data Omnipod two leading presentation outcomes therapy. one peer-reviewed drive broad the important aged front, a states shared on performance coming on different published injections outcomes. had span June. in areas, upcoming as accepted directly preschool international living Omnipod five abstracts Collectively, five and Also with additional including for impactful these or several clinical as groups across of can people number multiple demonstrate publications have of of improved the we life conferences daily These people range and of well at children, transition in We age improved recently diabetes diabetes forms outcomes domestic These type disease quality and from multiple in a to either
our expand preschoolers to and We continue clinically road and a HX two secure map, have to including work five to invest indication type compelling Omnipod to to a our indication. down
phase which first is XX-month continue outcomes The durable study planned which phase, progressing elected on to collect participants are our and allows all us do. of complete, through longer our to they X, allows we trial and Omnipod our preschool to well extension
two fully study type are the illuminating. is our feasibility now Additionally, and enrolled results
commitment early underserved for we further and doubled range that During our results will published that Bruce to with people Bode presented for market and to ENDO eight evidence of clinical opportunity type two that encouraging this in outcomes XXXX, diabetes. strong largely two how living will population. first just X, tremendous clinical innovate data from Insulet, and presented for to more offers type than Omnipod and study the the penetrate showed insulin-dependent The building this quarter improve time continue data last depth breadth Omnipod in weeks. demonstrates supports Dr. to continue The diabetes our with
advance our five sharing the data to pipeline, additional Omnipod is look our innovation to continue priority. We forward future. clinical top we and in
Dexcom beyond. our and However, to requires critical future software that data and Omnipod our advance with robust over generations term long products products This success of of areas includes well science a the that we five the are Abbott. extends integration development, competencies. as such diligently leadership and by pipeline other in next working know We core
have significant to living value product two type believe innovations diabetes. Beyond both offer with begun we and will Omnipod development X, we that on type people one
Moving global expansion. to
of Middle number new We year, are in entered we and within markets. Europe five expanding access and the Last a awareness of East. Omnipod countries attractive
we later gear into Australia in expanded Turkey, up an continued we and expected for to launch this year. quarter, This
world. footprint, efforts market. technology expansion to diabetes that see we million international international huge DASH and to The around to grow there has XX and our total living XX global five million attractive work the a underway highly opportunities our bring people is drive Omnipod bring further addressable our are future our international living market to been will people current Our will with launch insulin-dependent addressable access to markets. Across of diabetes. with We Omnipod expansion successful estimate
manufacturing significantly continue we invest to Lastly, in operations. our global
We the that are well expansion broader for innovation pipeline demand is commercial plans. do Omnipod DASH Omnipod our of meet as excellence launch key to future. well so the and enabling of and Operational consumer positioned will imperatives is growing one international today future strategic our well X, into growth our as
part As Insulet is sustainable strategy, growth. and of to responsible committed this
priorities. ESG We sustainability to report, highlights have affect the developed sustainability planet. to and our and considers strategy upon our most published and capabilities, business, XXXX which key a ESG society our value important our outlines addressing our our issues important We comprehensive builds that commitment issues stakeholders provides existing that recently
and are to our strong our start our closing, we business and communities In of us Insulet thrive. at business to that practices off are a employees in help All resiliency responsible dedicated customers, XXXX. a
to to expect and Omnipod launch deliver the in to with life-changing over year I'll to Wayde. lives. double-digit innovations revenue another order their diabetes improve simplify people five call We of bring advance turn now continue innovation to growth, pipeline to our and
